Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Viking Therapeutics Inc shares valued at $216,492 were sold by Mancini Marianna on Oct 28 ’25. At $35.00 per share, Mancini Marianna sold 6,185 shares. The insider’s holdings dropped to 382,467 shares worth approximately $13.47 million following the completion of this transaction.
Also, Rowland Charles A Jr sold 60,000 shares, netting a total of over 2,134,278 in proceeds. Following the sale of shares at $35.57 each, the insider now holds 30,000 shares.
Before that, Lian Brian had sold 38,989 shares from its account. In a trade valued at $1,364,923, the President & CEO traded Viking Therapeutics Inc shares for $35.01 each. Upon closing the transaction, the insider’s holdings decreased to 38,989 shares, worth approximately $85.2 million.
As published in their initiating research note from Canaccord Genuity on October 29, 2025, Viking Therapeutics Inc [VKTX] has been a Buy and the price target has been revised to $106. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in late April. As of April 08, 2025, Goldman has initiated its “Neutral” rating for VKTX. Earlier on February 13, 2025, Scotiabank initiated its rating. Their recommendation was “a Sector outperform” for VKTX stock.
Analyzing VKTX Stock Performance
On last trading session, Viking Therapeutics Inc [NASDAQ: VKTX] rose 0.83% to $35.22. The stock’s lowest price that day was $34.84, but it reached a high of $36.45 in the same session. During the last five days, there has been a surge of approximately 12.09%. Over the course of the year, Viking Therapeutics Inc shares have dropped approximately -54.86%. Shares of the company reached a 52-week high of $43.55 on 01/06/25 and a 52-week low of $18.92 on 04/09/25.
Support And Resistance Levels for Viking Therapeutics Inc (VKTX)
According to the 24-hour chart, there is a support level at 34.56, which, if violated, would cause prices to drop to 33.89. In the upper region, resistance lies at 36.17. The next price resistance is at 37.11. RSI (Relative Strength Index) is 60.74 on the 14-day chart, showing neutral technical sentiment.
Is Viking Therapeutics Inc subject to short interest?
Stocks of Viking Therapeutics Inc saw a sharp steep in short interest on 2025-10-15 dropping by -1.56 million shares to 25.45 million. Data from Yahoo Finance shows that the short interest on 2025-09-15 was 27.01 million shares. A decline of -6.13% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.7 of the overall float, the days-to-cover ratio (short ratio) decline to 4.7.
Which companies own the most shares of Viking Therapeutics Inc (VKTX)?
In terms of Viking Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 105 in the next 12 months, up nearly 200.6% from the previous closing price of $34.93. Analysts anticipate Viking Therapeutics Inc stock to reach 106 by 2025, with the lowest price target being 102. In spite of this, 7 analysts ranked Viking Therapeutics Inc stock as Buy at the end of 2025. On February 07, 2025, Citigroup assigned a price target of “a Neutral” to the stock and initiated coverage with a $38.
